Using phospholipids as hepatoprotective agents for dyslipidemia correction in adolescents with metabolic syndrome

Aim. To study the effect of phospholipids for lipid metabolism normalization in adolescents with metabolic syndrome. Methods. The study included 50 adolescents aged 12 to 17 years with the diagnosis of metabolic syndrome according to 2007 criteria of International Diabetes Federation. All of them had dyslipidemia and nonalcoholic fatty liver disease in the stage of steatosis, steatohepatitis. The adolescents were splitted into two groups: the treatment group (30 patients) and the control group (20 patients). Patients of the first group, as an addition to the standard treatment (metformin), took phospholipids (Rezalut) 2 capsules three times a day for 2 months, followed by a second course after 2 months gap. Patients of the first group were treated by the standard treatment only. The statistical analysis was performed by the methods of parametric and nonparametric statistics using «Statistica 6.0» software. Results. After 3 months of treatment, there was a body weight and body mass index decrease in patients of the treatment group, the difference between the groups was statistically significant (р <0.05), and preserved so after 6 months of treatment compared both to baseline data and to controls. Serum cholesterol, low-density lipids levels decreased, high-density lipids levels increased in patients of the first group, reducing the atherogenic index of plasma. No significant changes of these parameters was observed in the second group. Liver enzymes (aspartate aminotransferase, alanine aminotransferase) levels reduced significantly (р <0.05) in the treatment group compared with baseline levels; no such changes were observed in the control group. Conclusion. Prescribing phospholipids as part of the complex treatment of the metabolic syndrome is pathogenically justified.

метаболический синдром, неалкогольная жировая болезнь печени, атерогенная дислипидемия, эссенциальные фосфолипиды